Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber Cancer Institute explains the data on enfortumab in post-platinum and immuno-oncology (I-O) bladder cancer in patients is impressive enough to possibly change future practice habits.
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content